The combination of AT/DT-NE#E (oral) with anti-PD1 further decreased the tumor mass by 141% and 132% compared to AT/DT-NE#E monotherapy and anti-PD1 monotherapy, respectively (Figure 5c). Here, PDCD1 is linked to neoplasm.